Literature DB >> 27777434

Feasibility of Repairing Defects Followed by Treatment with Pulmonary Hypertension-specific Drugs (Repair and Treat) in Patients with Pulmonary Hypertension Associated with Atrial Septal Defect: Study Protocol for Interventional Trial.

Satoshi Akagi1, Kazufumi Nakamura, Teiji Akagi, Koji Nakagawa, Yoichi Takaya, Toshihiro Sarashina, Kentaro Ejiri, Hiroshi Ito.   

Abstract

A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27777434     DOI: 10.18926/AMO/54600

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  2 in total

Review 1.  Atrial septal defect (ASD) device trans-catheter closure: limitations.

Authors:  Alessia Faccini; Gianfranco Butera
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  MicroRNA‑15a‑5p induces pulmonary artery smooth muscle cell apoptosis in a pulmonary arterial hypertension model via the VEGF/p38/MMP‑2 signaling pathway.

Authors:  Wenmei Zhang; Yanna Li; Xin Xi; Guangfa Zhu; Shenghao Wang; Yan Liu; Man Song
Journal:  Int J Mol Med       Date:  2019-12-18       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.